RadFollow
Sign in
Guideline Current RECIST Working Group 2009

RECIST 1.1

Response Evaluation Criteria In Solid Tumors, version 1.1. Categorises tumor response as CR, PR, SD, or PD based on change in sum of target lesion diameters and appearance of new lesions.

Structured reportUpdated Jul 5, 2026
Applies to
  • Oncology patients undergoing treatment response assessment
  • Solid tumors with measurable disease on CT or MRI
Classification
  • Response CR
  • Response PR
  • Response SD
  • Response PD
Exclusions
  • Hematologic malignancies
  • Immunotherapy-specific response assessment (use iRECIST)
Interactive

Decision tree

Enter a finding to compute a recommendation without leaving the page.

Recommendation builder

Enter baseline and current sums of target-lesion longest diameters (mm). Response category is computed automatically. New lesions → PD.

Evidence

References

  1. PrimaryEisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
FAQ

Frequently asked

Does this guideline apply to oncology patients?

No — patients with known malignancy fall outside the scope unless the guideline states otherwise. Follow oncologic surveillance protocols instead.